Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 5, 2008, Pages 371-377

  Schmid, Ursula ^a   Stopper, Helga ^a   Heidland, August ^a   Schupp, Nicole ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Advanced glycation end products; Diabetic complications; DNA damage; In vitro; Oxidative stress; Vitamin B1

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ANGIOTENSIN II; BENFOTIAMINE; DNA; INDICAN; PEPTIDE HORMONE; THIAMINE; TRANSKETOLASE; UREMIC TOXIN;

ANALYTIC METHOD; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; COMET ASSAY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DNA DAMAGE; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL CULTURE; MICRONUCLEUS TEST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRUCTURE ANALYSIS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; DNA DAMAGE; HUMANS; LLC-PK1 CELLS; OXIDATIVE STRESS; RATS; THIAMINE; TRANSKETOLASE;

EID: 46349083981     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.860     Document Type: Article

References (28)

1. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
2. Aragno M, Parola S, Brignardello E, et al. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes 2000; 49: 1924-1931.
3. Aragno M, Mastrocola R, Medana C, et al. Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented by antioxidant treatment. Endocrinology 2005; 146: 5561-5567.
4. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
5. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
6. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol 2006; 54: 405-419.
7. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006; 11: 294-329.
8. Malecka SA, Poprawski K, Bilski B. Prophylactic and therapeutic application of thiamine (vitamin B1)-a new point of view. Wiad Lek 2006; 59: 383-387.
9. Abbas ZG, Swai AB. Evaluation of the efficacy of thiamine and pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy. East Afr Med J 1997; 74: 803-808.
10. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003; 31: 1423-1425.
11. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299.
12. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 1996; 34: 47-50.
13. Arima Y, Nishigori C, Takeuchi T, et al. 4-Nitroquinoline 1-oxide forms 8-hydroxydeoxyguanosine in human fibroblasts through reactive oxygen species. Toxicol Sci 2006; 91: 382-392.
14. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63: 1671-1680.
15. Haber E. Angiotensin-converting enzyme and lipoprotein(a) as risk factors for myocardial infarction. Circulation 1995; 91: 1888-1890.
16. Schupp N, Schmid U, Rutkowski P, et al. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am J Physiol 2007; 292: F1427-F1434.
17. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004; 26: 249-261.
18. Decordier I, Kirsch-Volders M. The in vitro micronucleus test: from past to future. Mutat Res 2006; 607: 2-4.
19. Fenech M. The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat Res 1993; 285: 35-44.
20. Singh N, McCoy M, Tice R, Schneider E. A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 1998; 175: 184-191.
21. Schupp N, Schinzel R, Heidland A, Stopper H. Genotoxicity of advanced glycation end proudcts: involvement of oxidative stress and of angiotensin II type I receptors. Ann N Y Acad Sci 2005; 1043: 685-695.
22. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 1999; 299: 15-27.
23. Pulido R, Bravo L, Saura-Calixto F. Antioxidant activity of dietary polyphenols as determined by a modified ferric reducing/antioxidant power assay. J Agric Food Chem 2000; 48: 3396-3402.
24. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of 'antioxidant power': the FRAP assay. Anal Biochem 1996; 239: 70-76.
25. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-2120.
26. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281: 9307-9313.
27. Cameron NE, Gibson TM, Nangle MR, Cotter MA. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 2005; 1043: 784-792.
28. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43: 71-77.